Literature DB >> 24282454

Regional differences in practice patterns and outcomes in patients treated with radical cystectomy in a universal healthcare system.

Bassel G Bachir1, Armen G Aprikian, Yves Fradet, Joseph L Chin, Jonathan Izawa, Ricardo Rendon, Eric Estey, Adrian Fairey, Ilias Cagiannos, Louis Lacombe, Jean-Baptiste Lattouf, David Bell, Fred Saad, Darrel Drachenberg, Wassim Kassouf.   

Abstract

INTRODUCTION: Our objective is to assess differences in practice patterns and outcomes across 3 regions in bladder cancer patients treated with radical cystectomy under a universal healthcare system.
METHODS: In total, we included 2287 patients treated with radical cystectomy at 8 Canadian centres from 1998 to 2008. Variables included various clinico-pathologic parameters, recurrence, and death stratified into different regions.
RESULTS: In total, 1105 patients were from the east region (group 1), 601 from the centre region (group 2), and 581 from the west region of Canada (group 3). The median follow-up of groups 1, 2, and 3 was 22.1, 17.1, and 28.6 months, respectively. Although the overall rate of neoadjuvant chemotherapy was low (3.1%), rates were higher in group 2 compared with groups 1 and 3 (p = 0.07). Continent diversions and extended lymphadenectomy were performed in 23.5%, 8.5%, 23.9% and 39.7%, 27.7%, 12.6% across groups 1, 2, and 3, respectively. There were statistically significant differences in gender distribution, performance of lymphadenectomy, presence of concomitant carcinoma in situ and lymphovascular invasion across the 3 groups. There were no differences among the 3 geographical locations in terms of stage, surgical margin status, and use of adjuvant chemotherapy. The mean number of days from the transurethral resection of the bladder tumour to cystectomy was 50, 79, 69 days for groups 1, 2, 3, respectively (p = 0.0006). The 5-year overall survival was 53.6%, 66.8%, and 52.4% for groups 1, 2 and 3, respectively (p < 0.0001).
CONCLUSIONS: Significant variations in practice patterns were noted across different geographic regions in a universal healthcare system. Use of continent diversions, extended lymphadenectomy, and neoadjuvant chemotherapy remains low across all 3 regions. Treatment delays are significant.

Entities:  

Year:  2013        PMID: 24282454      PMCID: PMC3840506          DOI: 10.5489/cuaj.201

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  28 in total

1.  A plea for a uniform surveillance schedule after radical cystectomy.

Authors:  Guido Dalbagni; Bernard H Bochner; Angel Cronin; Harry W Herr; S Machele Donat
Journal:  J Urol       Date:  2011-04-15       Impact factor: 7.450

2.  Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2.

Authors:  Amir Sherif; Erkki Rintala; Oddvar Mestad; Jonas Nilsson; Lars Holmberg; Sten Nilsson; Per-Uno Malmström
Journal:  Scand J Urol Nephrol       Date:  2002

3.  Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.

Authors: 
Journal:  Eur Urol       Date:  2005-04-25       Impact factor: 20.096

Review 4.  Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

Authors:  Arnulf Stenzl; Nigel C Cowan; Maria De Santis; Markus A Kuczyk; Axel S Merseburger; Maria José Ribal; Amir Sherif; J Alfred Witjes
Journal:  Eur Urol       Date:  2011-03-23       Impact factor: 20.096

5.  Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy.

Authors:  Matthias May; Edwin Herrmann; Christian Bolenz; Arne Tiemann; Sabine Brookman-May; Hans-Martin Fritsche; Maximilian Burger; Alexander Buchner; Christian Gratzke; Christian Wülfing; Lutz Trojan; Jörg Ellinger; Derya Tilki; Christian Gilfrich; Thomas Höfner; Jan Roigas; Mario Zacharias; Sven Gunia; Wolf F Wieland; Markus Hohenfellner; Maurice S Michel; Axel Haferkamp; Stefan C Müller; Christian G Stief; Patrick J Bastian
Journal:  Eur Urol       Date:  2011-01-28       Impact factor: 20.096

6.  Variation in use of lymph node dissection during radical cystectomy for bladder cancer.

Authors:  Ryan C Hedgepeth; Yun Zhang; Ted A Skolarus; Brent K Hollenbeck
Journal:  Urology       Date:  2010-12-09       Impact factor: 2.649

7.  High expression of karyopherin-α2 defines poor prognosis in non-muscle-invasive bladder cancer and in patients with invasive bladder cancer undergoing radical cystectomy.

Authors:  Jørgen Bjerggaard Jensen; Pia Pinholt Munksgaard; Christoffer Mørk Sørensen; Niels Fristrup; Karin Birkenkamp-Demtroder; Benedicte Parm Ulhøi; Klaus Møller-Ernst Jensen; Torben F Ørntoft; Lars Dyrskjøt
Journal:  Eur Urol       Date:  2011-02-16       Impact factor: 20.096

8.  Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study.

Authors:  Shahrokh F Shariat; Pierre I Karakiewicz; Guilherme Godoy; Jose A Karam; Raheela Ashfaq; Yves Fradet; Hendrik Isbarn; Francesco Montorsi; Claudio Jeldres; Patrick J Bastian; Matthew E Nielsen; Stefan C Müller; Arthur I Sagalowsky; Yair Lotan
Journal:  Clin Cancer Res       Date:  2009-11-10       Impact factor: 12.531

9.  Overexpression of EIF-5A2 is an independent predictor of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy.

Authors:  Wei Chen; Jun-Hang Luo; Wen-Feng Hua; Fang-Jian Zhou; Marie C Lin; Hsiang-Fu Kung; Yi-Xin Zeng; Xin-Yuan Guan; Dan Xie
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01-20       Impact factor: 4.254

10.  Pelvic lymphadenectomy in the treatment of invasive bladder cancer: literature review.

Authors:  Ehab A Elzayat; Ali A Al-Zahrani
Journal:  Adv Urol       Date:  2011-08-29
View more
  6 in total

1.  [Not Available].

Authors:  Christopher M Booth; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

2.  Delivering high-quality care to patients with muscle-invasive bladder cancer: Insights from routine practice in Ontario.

Authors:  Christopher M Booth; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

3.  Functional characterization of the tumor suppressor CMTM8 and its association with prognosis in bladder cancer.

Authors:  Shiying Zhang; Xiaolei Pei; Hao Hu; Wenjuan Zhang; Xiaoning Mo; Quansheng Song; Yingmei Zhang; Kexin Xu; Ying Wang; Yanqun Na
Journal:  Tumour Biol       Date:  2015-11-28

4.  Regional Clinical and Biochemical Differences among Patients with Primary Hyperparathyroidism.

Authors:  Özer Makay; Beyza Özçınar; Turgay Şimşek; Cumhur Arıcı; Bülent Güngör; Serdar Özbaş; Tamer Akça; Ali Uğur Emre; Güldeniz Karadeniz Çakmak; Müfide Akçay; Bülent Ünal; Mustafa Girgin; Sadullah Girgin; Semih Görgülü; Atakan Sezer; Adem Karataş; İbrahim Ali Özemir; Nihat Aksakal; Serap Erel; M Ümit Uğurlu; Ali İlker Filiz; Can Atalay; Ali Uzunköy; Uğur Deveci; Çetin Kotan; Gökhan İçöz; Yavuz Kurt; Abut Kebudi; N Zafer Cantürk; Yeşim Erbil; Rumen Pandev; Bahadır M Güllüoğlu
Journal:  Balkan Med J       Date:  2017-01-05       Impact factor: 2.021

5.  Is survival after radical cystectomy for bladder cancer in Saudi patients different from that of Western patients?

Authors:  Alaa Mokhtar; Mohamed Matar Al; Waleed Mohamad Al; Khalid Al Othman; Said A Kattan; Mohammed Faihan Al
Journal:  Ann Saudi Med       Date:  2017 May-Jun       Impact factor: 1.526

6.  Impact of stage and comorbidities on five-year survival after radical cystectomy in Poland: single centre experience.

Authors:  Bartosz Dybowski; Krzysztof Ossoliński; Anna Ossolińska; Michał Peller; Ewa Bres-Niewada; Piotr Radziszewski
Journal:  Cent European J Urol       Date:  2015-10-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.